You just read:

Parkinson's Disease: ProMIS Neurosciences Identifies Several Antibody Drug Candidates Showing Best-in-Class Selectivity for Toxic Forms of Alpha-Synuclein Compared to other Therapeutic Antibodies in Development

News provided by

ProMIS Neurosciences Inc.

Feb 12, 2019, 07:30 ET